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Abstract
Background: Erythropoietic protoporphyria (EPP) and X-linked Protoporphyria
(XLP) are rare photodermatoses presenting with severe phototoxicity. Although
anecdotally, providers who treat EPP patients acknowledge their life-altering
effects, tools that fully capture their impact on quality of life (QoL) are lacking.
Methods: Adult patients with EPP/XLP were given four validated QoL tools:
the Patient Reported Outcomes Measurement Information System 57 (PROMIS-
57), the Hospital Anxiety and Depression Scale (HADS), the Illness Perception
Questionnaire Revised (IPQR), and an EPP-Specific tool. All patients received
the PROMIS-57 while the HADS, IPQR, and EPP-Specific tools were intro-
duced at a later date. Associations between responses and clinical phenotypes
were explored.
Results: Two hundred and two patients were included; 193 completed PROMIS-
57, 104 completed IPQR, 103 completed HADS, and 107 completed the EPP-
Specific tool. The IPQR showed that patients strongly believed EPP/XLP had a
negative impact on their lives. Mean scores in anxiety and depression domains of
both HADS and PROMIS-57 were normal; however, anxiety scores from HADS
were borderline/abnormal in 20% of patients. The EPP-Specific tool revealed a
decreased QoL in most patients. The PROMIS-57 showed that 21.8% of patients
have clinically significant pain interference. Several tool domains correlated with
measures of disease severity, most being from the PROMIS-57.
Conclusions: Impaired QoL is an important consequence of EPP/XLP. PROMIS-
57 was most sensitive in evaluating impaired QoL in EPP/XLP. Further research is
needed to compare the effectiveness of it for assessing response to treatment.
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1 | INTRODUCTION
Erythropoietic protoporphyria (EPP) and X-linked prot-
oporphyria (XLP) are rare, inherited photodermatoses that
result in overproduction of erythrocyte protoporphyrin-IX
(ePPIX). They present with childhood-onset, severe, painful
phototoxicity.1-3
Sun-exposed skin, typically on the face and dorsum of
the hands, reacts with tingling, burning, and/or itching that
may progress rapidly to severe pain, erythema, and swell-
ing.4 Severity is variable, but most patients can only tolerate
<30 minutes of sun exposure.2,5,6 The pain can be excruciat-
ing, does not respond well to analgesics, including opioids,
and may last for days.2,4 The disease necessitates avoiding
sunlight as much as possible, which greatly interferes with
daily life. As visible blistering is atypical, and chronic skin
changes develop slowly or may be overlooked or absent, the
diagnosis is often delayed. Management is limited to sun-
protection, as there are currently no FDA-approved thera-
pies. Due to these severe phototoxic reactions, patients
typically develop a conditioned behavior to avoid sunlight,
which greatly limits their daily activities.5,7 However, effects
on quality of life (QoL) are not well described, and the tools
most effective for assessing this are not defined.
The dermatology life quality index (DLQI), which has been
validated for conditions like eczema and vitiligo,5,8 was previ-
ously used to assess 176 adults with EPP, and showed that
70% of patients indicated EPP had a large effect on their life in
the preceding week.5 Additionally, porphyrin levels and time
to onset of symptoms were correlated with DLQI scores.5
An EPP-specific QoL tool was developed for clinical trials
evaluating afamelanotide, a synthetic analog of α-melanocyte
stimulating hormone. It demonstrated increased pain-free sun
exposure and improved QoL in adults with EPP.9 The DLQI
was also used and was uninformative when measuring treat-
ment response.9
Although the DLQI and EPP-QoL have been the main
tools used to assess QoL in EPP, they have significant limi-
tations. The DLQI was designed for dermatologic conditions
with both visible skin lesions and effective treatment. The
EPP-Specific QoL tool asks questions about how the disease
affects daily activities (attending school/work, interference
with outdoor activities, and so on), and interprets most ques-
tions as a “disease severity” domain. Neither specifically
assesses the severe pain and conditioned response to avoid
sunlight, and how this impacts QoL. Having a robust QoL
tool for this population will be important not only for accu-
rately characterizing EPP patients' well-being, but also for
assessing the efficacy of potential new therapies. To address
this we evaluated four tools in a large US cohort of adult
EPP patients to identify which is most sensitive to disease
specific QoL issues.
2 | MATERIALS AND METHODS
The studies (NCT01561157 and NCT01688895) were per-
formed at six sites of the Porphyrias Consortium of the Rare
Diseases Clinical Research Network and conducted in
accord with the Declaration of Helsinki. Each site's Institu-
tional Review Board approved the study and informed con-
sent was obtained. Study procedures were described
previously.6 All patients included had a confirmed diagnosis
of EPP with significantly elevated ePPIX. Patients
≥18 years old were given paper copies of the Patient
Reported Outcomes Measurement Information System
57 (PROMIS-57) Version 1 scale,10 and a sub-set also com-
pleted, in no specific order, the Hospital Anxiety and
Depression Scale (HADS),11 the Illness Perception Ques-
tionnaire Revised (IPQR),12 and a modified EPP-Specific
QoL tool. A protocol modification to add the HADS, IPQR,
and EPP-Specific tools was done after study initiation, there-
fore not all subjects received all tools. The order in which
the tools was given was not randomized. These tools, includ-
ing PROMIS-57, were chosen after careful review of the
domains they capture and discussion among the investiga-
tors regarding what are relevant issues for EPP patients, and
gaps in current knowledge. The recall period of 2 months
for the EPP-Specific tool was changed to 1 week to align
with the other tools to allow for better comparison, and
because investigators felt the longer time period might gen-
erate too much variability,13-15 as EPP symptoms are
affected by weather and season, 2 months captures a long
length of time where these may change. Table 1 lists the
tools, what they measure, briefly describes the scoring
methods, and interpretation of scores. The HADS was modi-
fied to include a single open-ended free text question asking
if patients would like to share anything else, responses to
this were analyzed thematically.16
3 | STATISTICAL ANALYSIS
All tools were scored according to established methods10-12
and the modified EPP-Specific tool was scored as previously
reported9 Differences in scores were assessed by sex, disease
SYNOPSIS
Quality of life in erythropoietic protoporphyria is
not well described as previous studies used derma-
tologic or treatment specific tools, this is the first
robust assessment of QoL tools, which found that
~20% of patients have significant pain interference,
and the PROMIS-57 is the most sensitive to disease
severity.
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(EPP vs XLP), reported medical diagnosis of depression
and/or anxiety (combined), either ongoing or in the past, and
history of abnormal liver enzymes (patient-reported history
or abnormal serum aminotransferase levels at enrollment)
using two-sample t-tests. Associations among scores and
clinical features assessing disease severity (time to first
symptom, recovery time, ePPIX levels, and so on) were
explored using Spearman's or Pearson's correlation coeffi-
cients as appropriate. These were selected as measures of
disease severity because investigators determined they were
important, or patients reported them as issues of concern.
Analyses were considered exploratory and conducted at the
0.05 significance level using SAS version 9.4 (SAS, Cary,
North Carolina).
4 | RESULTS
The cohort included 202 adults with a mean age at enroll-
ment of 40.9 years (SD 14.5, range 18-77), and
180 (89.1%) EPP and 22 (10.9%) XLP patients. There
were approximately equal numbers of males and females
of both EPP and XLP patients; 94 EPP males and
86 females, and 10 XLP males and 12 females. Mean age
at onset of symptoms was 4.4 years (SD 4.4; Table 2).
Comparisons of responses for each tool between sex
(males vs females) and disease (EPP vs XLP) were
unremarkable. Characteristics of this cohort have been
previously reported, however only the portion who com-
pleted these tools is reported here.6 Of the 202 patients,
104 completed the IPQR, 103 completed the HADS,
107 completed the EPP-Specific tool, and 193 completed
the PROMIS-57; 101 patients completed all of the tools.
The demographics and disease characteristics of patients
completing all tools was similar to the overall cohort, with
the exception of the proportion of patients with a history
of liver enzyme abnormalities (23.5% vs 31.9% for those
who completed all tools vs the total cohort).
4.1 | Descriptive statistics and summary scores
4.1.1 | Illness Perception Questionnaire-
Revised
The IPQR was completed by 104 patients (96 EPP, 8 XLP;
Table 3). The higher scores (>20) on the timeline and conse-
quences domains reflect overall strong beliefs that the dis-
ease is chronic and has a negative impact. The moderate
cyclical domain scores indicate that the disease is viewed as
persistent rather than cyclic. Control scores indicate that
patients believed they understood their disease and had per-
sonal control over it (high coherence and personal control
domain scores), but felt that effective treatment was lacking
(low treatment control scores, Table 2). High emotional rep-
resentation scores reflect that the disease negatively affects
patients' mood.
4.1.2 | Hospital Anxiety and Depression Scale
The HADS was completed by 103 patients (95 EPP,
8 XLP), and mean scores for anxiety and depression were
within the normal range (Table 3); however, 20% (21/103)
of patients had borderline or abnormal anxiety levels, and
9.7% (10/103) had borderline or abnormal depression levels.
TABLE 2 Characteristics of patient sample
N = 202 %
EPP 180 89.1
Male 94 46.5
Female 86 42.5
XLP 22 10.9
Male 10 4.9
Female 12 5.9
Age at enrollment Mean 40.9, SD 14.5
Age at onset of symptoms Mean 4.4, SD 4.4
Time to first symptom N = 191
<10 min 58 28.7
11-30 min 69 34.2
31-60 min 28 13.9
1-3 h 30 14.9
>3 h 6 3.0
Unknown/not reported 11 5.4
Recovery time N = 195
4-24 h 6 3.0
1-3 days 119 58.9
4-7 days 62 30.7
>7 days 8 4.0
Unknown/not reported 7 3.5
Number of phototoxic episodes in past
year
N = 194
1-2 44 21.8
3-10 90 44.6
11-30 39 19.3
31-60 8 4.0
>60 13 6.4
Unknown/not reported 8 4.0
History of abnormal liver enzymes
N = 191
61 31.9
History of depression and/or anxiety 39 19.3
12 NAIK ET AL.
When asked “feel free to make any additional comments
about how your illness has affected your quality of life” at
the end of the HADS, 49 patients responded. Open
responses revealed that many patients thought about what
their lives could have been without EPP, and how their
symptoms significantly impacted them:
“EPP has made my life very lonely and iso-
lated…If there is an occasion where I must go
in the sun…I become very apprehensive and
agitated”
“I am not who I could have been.”
“As a child EPP was "torture" in my mind. The
rashes, scars & sun avoidance were extreme
issues in my life…The stigma of being a
"freak" was an emotional toll. As an adult, I
learned to accept the EPP.”
4.1.3 | Modified EPP-Specific QoL
Higher scores for the S domain reflect lower severity, and for
the Q domain higher satisfaction/QoL. Mean scores of the
107 patients who completed this tool are shown in Table 3.
There are no predetermined cut-offs for this tool to specify
low vs high QoL. However, the mean score of 30.8 on the Q
domain, well below the maximum score of 100, likely indi-
cates decreased QoL. Cronbach's alpha was 0.95, showing
good internal consistency of this modified tool.
4.1.4 | PROMIS-57
Of the 202 patients, 193 adults completed the PROMIS-57,
mean scores for each domain were similar to the general
population (Table 3). A higher PROMIS score represents
more of the domain being measured. For example higher
TABLE 3 IPQR, HADS, modified EPP-specific QoL, and PROMIS scores
Domains N
Score
Mean SD Range Maximum possible
IPQRa
Timeline 104 23.4 2.2 13-25 25
Consequences 23.2 4.3 12-30 30
Personal control 19.0 4.9 9-28 30
Treatment control 9.2 2.8 2-15 15
Illness coherence 19.0 4.2 7-25 25
Timeline-cyclical 10.5 3.8 4-20 20
Emotional representations 18.8 5.5 6-30 30
HADS
Anxiety 103 4.6 4.1 0-19 21
Depression 1.9 2.1 0-10
EPP-specific QoL
S domain 107 58.9 32.6 0-100 100
Q domain 30.8 27.4 0-100
Total score 54.3 30.0 0-100
Domains N
Score
Number of patients
with >1 SD impairment (%)
Maximum
possibleMean SD Range
Adult PROMIS
Pain interference 193 50.5 10.3 40-77 42 (21.8) 100
Depression 192 44.9 8.7 38-72 13 (6.8)
Anxiety 192 47.4 10.3 37-83 23 (12.0)
Fatigue 193 48.2 11.1 33-78 28 (14.5)
Physical function 192 51.9 8.3 20-59 16 (8.3)
Sleep disturbance 193 49.5 8.9 30-74 20 (10.4)
Satisfaction with social role 188 53.5 10.2 27-66 15 (8.0)
aA modified version without the identity component was used as it was not applicable in EPP.
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anxiety scores mean greater anxiety, where a score of 60 is
one SD worse than the general population average of
50, while higher physical function scores mean better physi-
cal functioning. The percentage of scores indicating >1 SD
of impairment, which can be considered clinically signifi-
cant, are shown in Table 2; notably 21.8% (42/193) of
patients have clinically significant pain interference.
4.2 | Associations of QoL tool scores with
disease severity
Table 2 shows the characteristics used to define disease sever-
ity for this cohort. Disease severity was variable for this
cohort with a wide range of patient-reported time to first
symptom. Most patients reported recovering from symptoms
within 1 to 3 days (61.0%), 31.9% reported a history of abnor-
mal liver enzymes or had abnormal results at baseline, and
19.3% reported a diagnosis of anxiety and/or depression. Of
those with a diagnosis of anxiety and/or depression, only four
patients reported that this was not an ongoing issue (4/39).
4.2.1 | Illness Perception Questionnaire
Revised
A history of liver enzyme abnormalities did not significantly
affect IPQR scores. Mean scores for the personal control,
treatment control, and emotional representations domains
were significantly worse for patients with a history of anxiety
and/or depression (Personal control: positive history mean
16.8 ± 5.0 vs negative history mean 19.5 ± 4.8 [P = .03];
Treatment control: positive history mean 7.6 ± 3.2 vs nega-
tive history mean 9.5 ± 2.6 [P = .009]; Emotional representa-
tions: positive history mean 22.8 ± 4.0 vs negative history
mean 17.9 ± 5.3 [P = .0004]). The consequences, treatment
control, and emotional representations domains also had sig-
nificant correlations with scores being higher in those with
shorter time to first symptoms (Spearman r = −0.38, P-
value = .0001; Spearman r = 0.20, P-value = .04; and
Spearman r = −0.30, P-value = .003, respectively). In addi-
tion, the consequences, timeline-cyclical, and emotional repre-
sentations domains had significant correlations with scores
being higher in those with longer recovery time (Spearman
r = 0.29, P-value = .003; Spearman r = 0.21, P-value = .04;
and Spearman r = 0.20, P-value = .05, respectively). None of
the domain scores were significantly correlated with number
of phototoxic episodes in the past year, baseline ePPIX levels,
or age at onset of symptoms.
4.2.2 | Hospital Anxiety and Depression Scale
Mean scores for anxiety and depression were not signifi-
cantly different between those with a history of liver enzyme
abnormalities and those without. A medical history of anxi-
ety and/or depression did affect mean scores for the anxiety
domain (positive history of anxiety mean 7.9 ± 5.2 vs nega-
tive history mean 3.9 ± 3.5 [P = .01]), however depression
scores were not significantly different. Anxiety and depres-
sion scores did not correlate with time to first symptom, but
did correlate with recovery time (anxiety domain Spearman
r = 0.20, P-value = .05; depression domain Spearman
r = 0.29, P-value = .003). The anxiety domain also had a
significant correlation with number of phototoxic episodes
(Spearman r = 0.21, P-value = .04). Scores were not signifi-
cantly correlated with ePPIX or age at onset of symptoms.
4.2.3 | Modified EPP-specific QoL
Neither a history of liver enzyme abnormalities nor anxiety
and/or depression affected mean scores for the modified
EPP-Specific QoL domains. But the severity domain was
significantly correlated with time to first symptom
(Spearman r = 0.47, P-value<.0001). Neither of the
domains was significantly associated with recovery time,
number of phototoxic episodes, ePPIX, or age at onset.
4.2.4 | PROMIS-57
Mean scores for physical function, fatigue, and satisfaction
with social role were significantly different between those
with a history of liver enzyme abnormalities and those with-
out (Figure 1). Pain interference, physical function, fatigue,
and satisfaction with social role scores were significantly
different by time to symptom onset after sun exposure
(Table 4). Pain interference and sleep disturbance were also
significantly associated with recovery time (Spearman
r = 0.18, P-values .01 and Spearman r = 0.18, P-value .02,
respectively). Pain interference was the only domain signifi-
cantly associated with the number of phototoxic episodes
(Spearman r = 0.17, P-value .02). Those who reported a his-
tory of anxiety and/or depression had significantly worse
mean scores for depression, fatigue, anxiety, and sleep dis-
turbance (Figure 1). Pain Interference scores significantly
correlated with ePPIX (Pearson r = 0.17, P-value = .03). No
correlations were observed with age at onset.
5 | DISCUSSION
EPP has a large impact on patient QoL. Our study examines
four validated QoL tools to determine which best captures
this. Previous studies in Europe used standard dermatologic
tools, which are limited as they do not assess all patient-
reported outcomes for EPP. EPP has unique symptoms and
implications for patients' lives. The only disease specific tool
for EPP was created for use in clinical trials assessing
14 NAIK ET AL.
afamelanotide,9 and validation studies have not been publi-
shed. A tool that is sensitive to all aspects of the disease is
lacking.
Clinical features in our cohort, such as age at onset and
time to first symptom, were consistent with previous
reports.5,17 The IPQR showed that patients believe their dis-
ease has a large negative impact on their lives, but that they
have some control in dealing with it. Understanding patients'
perceptions is critical to providing appropriate counseling;
however, it is unlikely that these perceptions will change
and administering this tool longitudinally may not be clini-
cally useful.
HADS scores revealed that ~20% of patients with EPP
had borderline or abnormal scores on the anxiety domain,
and ~10% had borderline or abnormal scores on the depres-
sion domain. In the United States 8.1% of adults over 20 had
depression, and the estimated lifetime prevalence of any
anxiety disorder is ~15%.18 Levels of anxiety and depression
for our cohort were not significantly different from general
population estimates. As well, the depression domain score
was not significantly associated with a history of anxiety
and/or depression, which is surprising. It is possible the
depression domain was not sensitive enough for this cohort,
or combining a history of anxiety with depression affected
these results. As only four patients had a history of
anxiety/depression that was in the past, it is unlikely this
affected the scores. Added free text responses in the HADS;
however, illustrated that patients struggle with isolation cau-
sed by EPP, and many felt the disease was particularly diffi-
cult to manage in childhood. Therefore, disease impact may
be more significant in children, and as adults they have
learned to cope.
FIGURE 1 EPP. PROMIS scores and history of anxiety/depression and liver enzyme abnormalities. Box plots of PROMIS scores across
seven domains by history of anxiety and/or depression is shown on the top row, and by history of liver enzyme abnormalities is shown on the
bottom row. For each domain, a higher PROMIS score represents more of the domain being measured. In each plot, the small circle inside the box
indicates the sample mean. The line inside the box is the median or 50th percentile. The bottom line of the box is the 1st quartile or 25th percentile
and the top line is the 3rd quartile or 75th percentile. The bottom “whisker” is the minimum observation within the lower fence and the top
“whisker” is the maximum observation within the upper fence. Lower fence is computed by Q1-1.5* (IQR; interquartile range) and upper fence is
computed by Q3 + 1.5*(IQR). Circle markers outside of the fences are defined as outliers
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The modified EPP-specific tool showed decreased QoL in
these patients, which is consistent with previous reports using
the original tool.5,9 However, this is the first study to use the
tool in a non-treatment setting. While we cannot exclude the
possibility that modifying the recall time affected the sensitiv-
ity of this tool, it is also possible that the tool is not ideal for
monitoring general QoL without a treatment.
Several of the PROMIS-57 domains had a relatively large
proportion of patients with >1 SD impairment, similar to
what has been observed when using these scales in other
chronic diseases.19 The pain interference domain had a par-
ticularly large proportion of patients with clinically signifi-
cant impairment. The PROMIS scales are considered
psychometrically robust and have been validated in several
TABLE 4 PROMIS scores and time to first symptom
Domains Time to first symptoma N Mean score SD Spearman r P-value
Pain interference <10 min 57 53.9 10.9 −0.23 0.0016
11-30 min 66 50.1 11.1
31-60 min 26 48.6 8.5
1-3 h 28 46.0 7.8
>3 h 6 50.0 8.0
Depression sadness <10 min 56 44.9 9.2 −0.11 0.14
11-30 min 66 46.8 8.3
31-60 min 26 44.1 9.2
1-3 h 28 42.2 7.5
>3 h 6 41.7 5.6
Anxiety fear <10 min 56 47.1 10.1 −0.04 0.57
11-30 min 66 48.7 11.3
31-60 min 26 47.9 9.0
1-3 h 28 44.5 9.0
>3 h 6 48.8 7.9
Fatigue <10 min 57 49.7 10.2 −0.16 0.03
11-30 min 66 49.0 12.0
31-60 min 26 47.5 10.4
1-3 h 28 43.8 11.0
>3 h 6 49.5 13.3
Physical function <10 min 56 49.0 10.1 0.25 0.0006
11-30 min 66 51.7 7.3
31-60 min 26 53.6 6.1
1-3 h 28 55.4 7.0
>3 h 6 54.7 7.9
Sleep disturbance <10 min 57 49.3 9.2 −0.07 0.35
11-30 min 66 51.9 8.5
31-60 min 26 49.5 7.0
1-3 h 28 46.6 8.8
>3 h 6 47.4 9.6
Satisfaction with social roles <10 min 54 51.0 10.8 0.22 0.003
11-30 min 65 52.4 10.2
31-60 min 25 57.3 7.1
1-3 h 28 56.3 10.3
>3 h 6 56.6 11.2
aSubjects who did not report their time to first symptoms were not included.
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diseases,19-21 but have not been used in many rare diseases.
Some questions may not be useful for EPP and may be limit-
ing the observed impact of their domains. As well, additional
studies are needed to determine if this tool is sensitive to
treatment response.
All the tool scores correlated with measures of disease
severity, some more so than others; however, the PROMIS
domains appeared to be the most sensitive. Several PROMIS
domains had significantly different scores by disease sever-
ity measures, specifically the pain interference, physical
function, and satisfaction with social roles domains. The
sensitivity of this tool should be further assessed to deter-
mine if the PROMIS domains can be used to track disease
progression over time. EPP pain is generally only considered
an issue during phototoxic reactions2; however, the pain
interference domain was significantly associated with sev-
eral markers of disease severity. This is striking as generally
the tools were administered while patients were in clinic and
not reporting active phototoxic reactions. Pain interference
may be more important to daily functioning than originally
suspected, even in patients who are adept at avoiding sun
exposure.
It is possible the PROMIS domains were identified as
most sensitive due to the larger sample size; however, the
representation of patients with various measures of disease
severity were varied enough in those who completed the
HADS, IPQR, and EPP-Specific to observe meaningful dif-
ferences in scores. In fact several of the other tools' domains
did associate with disease severity measures. However, the
PROMIS domains are likely most sensitive because they
cover a more varied set of domains than the other tools.
There are several factors which impact the accuracy of
measuring QoL in EPP patients. The tools compared in this
study use a 7-day recall, but wide variations in weather and
amount of time that can be spent in the sun may affect
results, and a longer recall period may be more appropriate
for this disease. However, accuracy is likely to decrease
were a longer recall period used.
Seasonality should also be considered, especially in the
context of measuring a treatment response. The EPP-
Specific QoL tool was analyzed for whether the scores var-
ied with the season during afamelanotide treatment.22 The
mean scores during winter months were higher than during
summer, suggesting better QoL in winter.22
Anecdotally, many patients have expressed to the investi-
gators that they struggle with answering these tools as they
have learned to cope with their disease over time, becoming
experts at avoiding situations, which may put them at risk of
developing phototoxic reactions. This is not captured as an
impact in existing tools, despite the fact that it greatly affects
patients' lives. We believe this leads to significant under-
reporting of the impact of EPP. Due to the nature of this
disease and lack of effective treatments, patients do not
experience what is “normal” or “improved,” but only com-
pare periods in their lives with and without efforts to avoid
sunlight.
EPP is the most common type of porphyria in children2;
many adults described struggling with the disease and being
depressed as children in the open response questions, and
found it particularly difficult to navigate school life.23
Therefore, it is critical to develop tools for assessing QoL
effects in children with EPP. Using such tool in clinical
practice can allow for early intervention, such as referring
to psychology, social work, or other services to help
patients cope, if responses show a decreased QoL score
over time.
The analyses assessing correlations with disease severity
were limited by the smaller number of patients who com-
pleted the IPQR, HADS, and modified EPP-Specific tools
compared to the PROMIS; however, results are still clini-
cally useful in assessing these tools. As well, seasonality and
geographic location were not accounted for in this study and
should be in future evaluations of QoL tools in this
population.
In conclusion, we compared four QoL tools in adult EPP
patients and determined that overall the PROMIS-57 is most
sensitive to disease severity. While this tool may be clini-
cally useful when evaluating patients, it may require supple-
mentation with disease-specific questions. An ideal QoL
tool would be both clinically useful and effectively measure
treatment response. A major goal of treatment is to enable
patients to spend more time in the sun, and freedom to do
this would greatly improve their QoL. Therefore measure-
ment of QoL has a central role in documenting improvement
in EPP.
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